FTC: drugmakers’ agreement was cover for illegal scheme
The Federal Trade Commission has argued that a 2010 agreement between Impax and Endo to develop a Parkinson’s treatment drug was a pretence for the first $10 million instalment Endo paid to keep a generic rival off the market.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10